FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2021/08/035625 [Registered on: 12/08/2021] Trial Registered Prospectively
Last Modified On: 08/08/2021
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   comparsion between two drugs for the treatment of facial pigmentation 
Scientific Title of Study   A comparartive study of the efficacy of once daily 4 % hydroquinone and 2% kojic acid cream for the treatment of facial melasma: A Randomized control trail 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  POOJA SUHAG 
Designation  JUNIOR RESIDENT -1 
Affiliation  ROHAILKHAND MEDICAL COLLEGE 
Address  ROOM NO.61 GIRLS HOSTEL,ROHAILKHAND MEDICAL COLLEGE AND HOSPITAL,BAREILLY,UP

Bareilly
UTTAR PRADESH
243006
India 
Phone  7082947447  
Fax    
Email  deepakahlawat68@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  PK RATHORE 
Designation  PROFESSOR AND HEAD OF DEPARTMENT 
Affiliation  ROHAILKHAND MEDICAL COLLEGE 
Address  ROHAILKHAND MEDICAL COLLEGE AND HOSPITAL,BAREILLY,UP

Bareilly
UTTAR PRADESH
243006
India 
Phone  9412332063  
Fax    
Email  drpraveenderma@gmail.com  
 
Details of Contact Person
Public Query
 
Name  PK RATHORE 
Designation  PROFESSOR AND HEAD OF DEPARTMENT 
Affiliation  ROHAILKHAND MEDICAL COLLEGE 
Address  ROHAILKHAND MEDICAL COLLEGE AND HOSPITAL,BAREILLY,UP

Bareilly
UTTAR PRADESH
243006
India 
Phone  9412332063  
Fax    
Email  drpraveenderma@gmail.com  
 
Source of Monetary or Material Support  
Rohilkhand medical college and hospital  
 
Primary Sponsor  
Name  ROHAILKHAND MEDICAL COLLEGE 
Address  ROHAILKHAND MEDICAL COLLEGE AND HOSPITAL,BAREILLY ,PILIBHIT BYPASS ROAD, UP/243006 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
POOJA SUHAG  Rohilkhand medical college and hospital   Room no.1197, OPD, DEPARTMENT OF DERMATOLOGY ROHAILKHAND MEDICAL COLLEGE AND HOSPITAL,BAREILLY ,PILIBHIT BYPASS ROAD, UP/243006
Bareilly
UTTAR PRADESH 
05812526153

drpoojasuhag@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
ROHAILKHAND MEDICAL COLLEGE and hospital   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: L811||Chloasma,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Hydroquinone  Cream, 4%, Local application, bedtime, for 4 month  
Comparator Agent  Kojic acid  Cream, 2%, Local application, bedtime, for 4 month 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1. Those who are willing for study
2. Moderate to severe melasma
3. Age (18-60) years.
4. Mentally stable, oriented and coherent patients. 
 
ExclusionCriteria 
Details  1. Pregnancy and Lactation
2. Melasma inducing drugs.
3. Patients on photosensitizing drugs or thyroid hormones.
4. Patients on Hormone replacement therapy 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Alternation 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
To reduce the Melasma Area and Severity Index (MASI) Score  4 month 
 
Secondary Outcome  
Outcome  TimePoints 
To improve the quality of life of the patients   6 months  
 
Target Sample Size   Total Sample Size="90"
Sample Size from India="90" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 1 
Date of First Enrollment (India)   31/08/2021 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan

  3. Who will be able to view these files?
    Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Data are available indefinitely at (Link to be included rmcbareilly@info.com).

  6. For how long will this data be available start date provided 21-12-2021 and end date provided 21-12-2022?
    Response - Immediately following publication. No end date.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary  

Melasma is a common, subtle, symptomless, evenness, and patterned hyperpigmentation. It has predisposition for involvement of the cheeks, forearm, nose, upper lip, and forhead arises as asymmetrical shaped, but many of times it is markedly described, speckles of dark  to light brown pigmentation in the fair complexion or dark ones in dark complexion individuals. It may be idiopathic, may appear during pregnancy or be associated with use of oral contraceptives . It Affects almost  all the races, but it is more commonly seen in Hispanics and Asians with  skin types IV, V, and VI with centrofacial , malar, and mandibular distribution. ultraviolet (UV) radiation have some role in occurrence of melasma in case of non pregnant women and in men.1

It is most prevalent in Southeast Asia, in 40 % in females and 20% in males. In Asia, aesthetic consultation of melasma are 50% . Occurs in 50-70% of pregnant women in USA and in 50 to 80 % of Latina women. Despite the fact melasma is developed after pregnancy in 41% of females and spontaneous remission is found only in 8% of the cases.  In case of Prevalence it is on   side  in females with a male to female ratio of approximately 4:1. Women with multiple pregnancies have higher incidence (51%) compared with single women (25%) or with no pregnancy (24%).2

Based on the distribution of the facial lesions, melasma can be classified into three types, namely malar, centrofacial, and mandibular patterns. Melasma can be classified as epidermal, dermal, mixed, and indeterminate variants  on the basis of wood’s lamp examination.

  Treatment of melasma is tough because of its dermal constituent and propensity to recurrence. The most usual  therapy in treating melasma  is to use broad-spectrum (UVA & UVB) sunscreen , as is topical hydroquinone used very often . Retinoic acid (tretinoin) and azelaic acid are the  opposite lightening agents employed in melasma.To increase the efficacy while treating the melasma combination therapies such as tretinoin, azelaic acid , hydroquinone and steriods have been used  as compared with monotherapy. Kojic acid, isopropylhcatechol, N-acetyl-4-cysteaminylphenol, and flavonoid extracts are Other compounds that have been isopropylcatechol, N- acetyl-4- cysteaminylphenol .4

Different techniques like depigmenting agents Hydroquinone , kojic and azelaic acids,) and keratolytic agents (tretinoine, glycolic and trichloroacetic acids) are being used but chemical peeling provides more  rapid response than topical therapy. Chemical peels create injury at a specific skin depth and causes exfoliation that stimulates new epidermal growth and collagen with more even distribution of melanin .5

On histologic finding of melasma is increase melanin content in of both dermis and epidermis, but the quantity varies with the severity of hyperpigmentation. In, most of the studies manifest no quantifiable rise in melanocytes; however, the melanosomes are more copious and cells are enlarged with distinguished and broaden dendrites. In additional to color change other finding are solar elastosis and photoaging, expression of endothelial growth factors and increased mast cells in dermal blood vessels.6 

Diagnosis and evaluation of treatment of melasma can be made by clinical examination, photography, woods lamp examination, dermoscopy and confocal microscopy. The severity of melasma can be estimated using colorimetry, mexametry and calculation of melasma area severity index (MASI).7

Since very few clinical trials based on the comparative study of efficacy and tolerability of hydroquinone and kojic acid have been performed, the centre of this study is mostly on the effectivness of topical kojic acid and hydroquinone acid, so as to determine an effective modality of treatment for melasma. Moreover, previous studies mainly focused on multidrug therapy and not on monotherapeutic drug therapy which has less side effects and are sufficiently less costly and this study is based on monotherapeutic drug therapy.

 
Close